← Eichor
Condition: Immune Cells Activity Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Immune Cells Activity

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Massage Impact on Sleep in Pediatric Oncology
NA · 2 location(s) · Children's Hospital of Philadelphia · NCT06892158A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
Phase 1/Phase 2 · 9 location(s) · NuCana plc · NCT03829254BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Phase 2 · 6 location(s) · Dana-Farber Cancer Institute · NCT05922761Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
NA · 1 location(s) · University of Nebraska · NCT04898790Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
Phase 1 · 1 location(s) · Christopher Strouse · NCT07581704A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T
Phase 1/Phase 2 · 13 location(s) · Cabaletta Bio · NCT04422912A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgki
Phase 1 · 16 location(s) · Sanofi · NCT06392477A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D)
Phase 2/Phase 3 · 49 location(s) · AbbVie · NCT07095452IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05365659A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Phase 1/Phase 2 · 21 location(s) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT07124936Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
Phase N/A · 1 location(s) · University of Bonn · NCT06460142Go-CHOP as the Frontline Therapy for PTCL
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05963347Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06287229A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034Myeloma Novel Drug Discovery Ver 1.2
Phase N/A · 1 location(s) · Institute of Cancer Research, United Kingdom · NCT05968417Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lym
Phase N/A · 1 location(s) · Janssen Cilag S.A.S. · NCT06299540Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Phase 1/Phase 2 · 19 location(s) · Cellectis S.A. · NCT04150497PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
NA · 1 location(s) · Pack Health · NCT05956457CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLL
NA · 1 location(s) · Technical University of Munich · NCT07487428Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
Phase 2 · 18 location(s) · Fondazione Italiana Linfomi - ETS · NCT04915248Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 10 location(s) · Cellectis S.A. · NCT05607420A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/Phase 2 · 68 location(s) · Turning Point Therapeutics, Inc. · NCT04094610Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07053059Impact of Aerobic Exercise on the Anticancer Immune Response in Patients Receiving Cancer Treatment
NA · 2 location(s) · Université de Sherbrooke · NCT06911970A New Study Evaluating the Activity of Modular CAR T for mYeloma
Phase 1 · 1 location(s) · University College, London · NCT04795882SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523542Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 · 11 location(s) · Jiangsu Simcere Pharmaceutical Co., Ltd. · NCT06375044A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcuta
Phase 1/Phase 2 · 48 location(s) · AbbVie · NCT06953960A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I
Phase 2 · 96 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07015983Promoting Response to IMmunotherapy by Exercise in Patients With Advanced Renal Cell Carcinoma
NA · 2 location(s) · Radboud University Medical Center · NCT07680556
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.